Cognitive impairment in patients with type 2 diabetes mellitus: the role of hypoglycemic therapy

N.V. Pashkovska

Abstract


The article presents data on epidemiology, risk factors, mechanisms of development, clinical features of cognitive impairment in patients with type 2 diabetes mellitus. The literature data about the dependence of the incidence and severity of cognitive impairment on the type of hypoglycemic therapy are analyzed. As well as the results of clinical and experimental studies concerning the peculiarities of cognitive functions against the background of using various antidiabetic agents — meglitinides, biguanides, thiazolidinediones, glucagon-like peptide-1 receptor agonists, dipeptidyl peptidase-4 inhibitors, sodium-dependent glucose cotransporter 2 inhibitors and insulin.

Keywords


type 2 diabetes mellitus; cognitive impairment; hypoglycemic therapy

References


Corriveau RA, Bosetti F, Emr M, et al. The Science of Vascular Contributions to Cognitive Impairment and Dementia (VCID): A Framework for Advancing Research Priorities in the Cerebrovascular Biology of Cognitive Decline. Cell Mol Neurobiol. 2016 Mar;36(2):281-8. doi: 10.1007/s10571-016-0334-7.

Riederer P, Korczyn AD, Ali SS, et al. The diabetic brain and cognition. J Neural Transm (Vienna). 2017 Nov;124(11):1431-1454. doi: 10.1007/s00702-017-1763-2.

Biessels GJ, Staekenborg S, Brunner E, Brayne C, Scheltens P. Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol. 2006;5(1):64-74. doi: 10.1016/S1474-4422(05)70284-2.

Ott A, Stolk RP, Van harskamp F, Pols HA, Hofman A, Breteler MM. Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology. 1999;53(9):1937-42. PMID: 10599761.

Cheng G, Huang C, Deng H, Wang H. Diabetes as a risk factor for dementia and mild cognitive impairment: a meta-analysis of longitudinal studies. Intern Med J. 2012 May;42(5):484-91. doi: 10.1111/j.1445-5994.2012.02758.x.

Samaras K, Sachdev PS. Diabetes and the elderly brain: sweet memories? Ther Adv Endocrinol Metab. 2012 Dec;3(6):189-96. doi: 10.1177/2042018812469645.

Dodd GT, Tiganis T. Insulin action in the brain: Roles in energy and glucose homeostasis. J Neuroendocrinol. 2017;29(10):e12513. doi: 10.1111/jne.12513.

Costello DA, Claret M, Al-Qassab H, et al. Brain deletion of insulin receptor substrate 2 disrupts hippocampal synaptic plasticity and metaplasticity. PLoS One. 2012;7(2):e31124. doi:10.1371/journal.pone.0031124.

Crane PK, Walker R, Hubbard RA, et al. Glucose levels and risk of dementia. N Engl J Med. 2013 Aug 8;369(6):540-8. doi: 10.1056/NEJMoa1215740.

Abbatecola AM, Rizzo MR, Barbieri M, et al. Postprandial plasma glucose excursions and cognitive functioning in aged type 2 diabetics. Neurology. 2006 Jul 25;67(2):235-40. doi: 10.1212/01.wnl.0000224760.22802.e8.

Laws SM, Gaskin S, Woodfield A, et al. Insulin resistance is associated with reductions in specific cognitive domains and increases in CSF tau in cognitively normal adults. Sci Rep. 2017 Aug 29;7(1):9766. doi: 10.1038/s41598-017-09577-4.

Shukla V, Shakya AK, Perez-Pinzon MA, Dave KR. Cerebral ischemic damage in diabetes: an inflammatory perspective. J Neuroinflammation. 2017 Jan 23;14(1):21. doi: 10.1186/s12974-016-0774-5.

Yun JS, Ko SH. Risk Factors and Adverse Outcomes of Severe Hypoglycemia in Type 2 Diabetes Mellitus. Diabetes Metab J. 2016 Dec;40(6):423-432. doi: 10.4093/dmj.2016.40.6.423.

Whitmer RA, Karter AJ, Yaffe K, Quesenberry CP Jr, Selby JV. Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus. JAMA. 2009 Apr 15;301(15):1565-72. doi: 10.1001/jama.2009.460.

Feinkohl I, Aung PP, Keller M, et al. Severe hypoglycemia and cognitive decline in older people with type 2 diabetes: the Edinburgh type 2 diabetes study. Diabetes Care. 2014 Feb;37(2):507-15. doi: 10.2337/dc13-1384.

De galan BE, Zoungas S, Chalmers J, et al. Cognitive function and risks of cardiovascular disease and hypoglycaemia in patients with type 2 diabetes: the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial. Diabetologia. 2009 Nov;52(11):2328-2336. doi: 10.1007/s00125-009-1484-7.

Bauduceau B, Doucet J, Le floch JP, Verny C. Cardiovascular events and geriatric scale scores in elderly (70 years old and above) type 2 diabetic patients at inclusion in the GERODIAB cohort. Diabetes Care. 2014;37(1):304-11. doi: 10.2337/dc13-1540.

Derakhshan F, Toth C. Insulin and the brain. Curr Diabetes Rev. 2013;9(2):102-16. PMID: 23231032.

Shpakov A, Chistyakova O, Derkach K, Bondareva V. Hormonal signaling systems of the brain in diabetes mellitus. Chapter 15 in: Chang RCC, ed. Neurodegenerative Diseases - Processes, Prevention, Protection and Monitoring. Rijeka, Croatia: InTech; 2011. 349-386 pp. doi: 10.5772/28930.

Kleinridders A, Ferris HA, Cai W, Kahn CR. Insulin Action in Brain Regulates Systemic Metabolism and Brain Function. Diabetes. 2014;63(7):2232-2243. doi:10.2337/db14-0568.

Williamson JD, Launer LJ, Bryan RN, et al. Cognitive Function and Brain Structure in Persons With Type 2 Diabetes Mellitus After Intensive Lowering of Blood Pressure and Lipid Levels: A Randomized Clinical Trial. JAMA intern med. 2014;174(3):324-333. doi:10.1001/jamainternmed.2013.13656.

Wu JH, Haan MN, Liang J, Ghosh D, Gonzalez HM, Herman WH. Impact of antidiabetic medications on physical and cognitive functioning of older Mexican Americans with diabetes mellitus: a population-based cohort study. Ann Epidemiol. 2003;13(5):369-76. PMID: 12821276.

Weinstock RS, Teresi JA, Goland R, et al. Glycemic Control and Health Disparities in Older Ethnically Diverse Underserved Adults With Diabetes: Five-year results from the Informatics for Diabetes Education and Telemedicine (IDEATel) study. Diabetes Care. 2011;34(2):274-279. doi:10.2337/dc10-1346.

Launer LJ, Miller ME, Williamson JD, et al. Effects of randomization to intensive glucose lowering on brain structure and function in type 2 diabetes ACCORD Memory in Diabetes Study. Lancet Neurology. 2011;10(11):969-977. doi:10.1016/S1474-4422(11)70188-0.

Griffin SJ, Leaver JK, Irving GJ. Impact of metformin on cardiovascular disease: a meta-analysis of randomised trials among people with type 2 diabetes. Diabetologia. 2017;60(9):1620-1629. doi:10.1007/s00125-017-4337-9.

Grzybowska M, Bober J, Olszewska M. Metformin – mechanisms of action and use for the treatment of type 2 diabetes mellitus. Postepy Hig Med Dosw (Online) 2011;65:277-285. PMID: 21677353. (in Polish).

Wang Y-W, He S-J, Feng X, et al. Metformin: a review of its potential indications. Drug Des Devel Ther. 2017 Aug 22;11:2421-2429. doi: 10.2147/DDDT.S141675.

Markowicz-piasecka M, Sikora J, Szydłowska A, Skupień A, Mikiciuk-olasik E, Huttunen KM. Metformin - a Future Therapy for Neurodegenerative Diseases : Theme: Drug Discovery, Development and Delivery in Alzheimer's Disease Guest Editor: Davide Bramb. Pharm Res. 2017 Dec;34(12):2614-2627. doi: 10.1007/s11095-017-2199-y.

Fatt M, Hsu K, He L, et al. Metformin Acts on Two Different Molecular Pathways to Enhance Adult Neural Precursor Proliferation/Self-Renewal and Differentiation. Stem Cell Reports. 2015;5(6):988-995. doi:10.1016/j.stemcr.2015.10.014.

Ge XH, Zhu GJ, Geng DQ, et al. Metformin protects the brain against ischemia/reperfusion injury through PI3K/Akt1/JNK3 signaling pathways in rats. Physiol Behav. 2017;170:115-123. doi: 10.1016/j.physbeh.2016.12.021.

Pintana H, Apaijai N, Pratchayasakul W, Chattipakorn N, Chattipakorn SC. Effects of metformin on learning and memory behaviors and brain mitochondrial functions in high fat diet induced insulin resistant rats. Life Sci. 2012;91(11-12):409-14. doi: 10.1016/j.lfs.2012.08.017. 

Hettich MM, Matthes F, Ryan DP, et al. The Anti-Diabetic Drug Metformin Reduces BACE1 Protein Level by Interfering with the MID1 Complex. PLoS One. 2014 Jul 15;9(7):e102420. doi: 10.1371/journal.pone.0102420.

Markowicz-Piasecka M, Sikora J, Mateusiak Ł, Mikiciuk-Olasik E, Huttunen KM. Metformin and Its Sulfenamide Prodrugs Inhibit Human Cholinesterase Activity. Oxid Med Cell Longev. 2017;2017:7303096. doi: 10.1155/2017/7303096.

Bibi F, Ullah I, Kim MO, Naseer MI. Metformin attenuate PTZ-induced apoptotic neurodegeneration in human cortical neuronal cells. Pak J Med Sci. 2017 May-Jun;33(3):581-585. doi: 10.12669/pjms.333.11996.

Cheng C, Lin CH, Tsai YW, Tsai CJ, Chou PH, Lan TH. Type 2 diabetes and antidiabetic medications in relation to dementia diagnosis. J Gerontol A Biol Sci Med Sci 2014;69(10):1299-1305. doi: 10.1093/gerona/glu073.

Ng TP, Feng L, Yap KB, Lee TS, Tan CH, Winblad B. Long-term metformin usage and cognitive function among older adults with diabetes. J Alzheimers Dis. 2014;41(1):61-8. doi: 10.3233/JAD-131901. 

Kuan YC, Huang KW, Lin CL, Hu CJ, Kao CH. Effects of metformin exposure on neurodegenerative diseases in elderly patients with type 2 diabetes mellitus. Prog Neuropsychopharmacol Biol Psychiatry. 2017;79(Pt B):77-83.  doi: 10.1016/j.pnpbp.2017.06.002.

Hervás D, Fornés-Ferrer V, Gómez-Escribano AP, et al. Metformin intake associates with better cognitive function in patients with Huntington’s disease. PLoS ONE. 2017;12(6):e0179283. doi:10.1371/journal.pone.0179283.

Luchsinger JA, Perez T, Chang H, et al. Metformin in Amnestic Mild Cognitive Impairment: results of a pilot randomized placebo controlled clinical trial. J Alzheimers Dis. 2016;51(2):501-14. doi:10.3233/JAD-150493.

Koenig AM, Mechanic-hamilton D, Xie SX, et al. Effects of the Insulin Sensitizer Metformin in Alzheimer Disease: Pilot Data From a Randomized Placebo-controlled Crossover Study. Alzheimer Dis Assoc Disord. 2017;31(2):107-113. doi: 10.1097/WAD.0000000000000202.

Herath PM, Cherbuin N, Eramudugolla R, Anstey KJ. The Effect of Diabetes Medication on Cognitive Function: Evidence from the PATH Through Life Study. BioMed Research International. 2016;2016:7208429. doi:10.1155/2016/7208429.

Imfeld P, Bodmer M, Jick SS, Meier CR. Metformin, other antidiabetic drugs, and risk of Alzheimer’s disease: a population-based case-control study. J Am Geriatr Soc. 2012;60(5):916-921. doi: 10.1111/j.1532-5415.2012.03916.x.

Moore EM, Mander AG, Ames D, et al. Increased Risk of Cognitive Impairment in Patients With Diabetes Is Associated With Metformin. Diabetes Care. 2013;36(10):2981-2987. doi:10.2337/dc13-0229.

Tasci I. Metformin: good or bad for the brain? Ann Transl Med. 2014;2(6):53. doi: 10.3978/j.issn.2305-5839.2014.06.06.

Zherdeva N. New page in metformin prescription. Praktykujuchyj likar. 2015;(13):65-67. (in Ukrainian).

Glukophazh® XR: new possibilities of compliance increase in metformin therapy. Mìžnarodnij endokrinologìčnij žurnal. 2009;(22):71-74. (in Russian)

Kravitz E, Schmeidler J, Schnaider Beeri M. Type 2 Diabetes and Cognitive Compromise: Potential Roles of Diabetes-Related Therapies. Endocrinol Metab Clin North Am. 2013 Sep;42(3):489-501. doi: 10.1016/j.ecl.2013.05.009. 

Watson GS, Cholerton BA, Reger MA, et al. Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. Am J Geriatr Psychiatry. 2005;13(11):950-8. doi: 10.1176/appi.ajgp.13.11.950.

Harrington C, Sawchak S, Chiang C, et al. Rosiglitazone does not improve cognition or global function when used as adjunctive therapy to AChE inhibitors in mild-to-moderate Alzheimer's disease: two phase 3 studies. Curr Alzheimer Res. 2011;8(5):592-606. PMID: 21592048.

Sato T, Hanyu H, Hirao K, Kanetaka H, Sakurai H, Iwamoto T. Efficacy of PPAR-γ agonist pioglitazone in mild Alzheimer disease. Neurobiol Aging. 2011;32(9):1626-33. doi: 10.1016/j.neurobiolaging.2009.10.009. 

Geldmacher DS, Fritsch T, McClendon MJ, Landreth G. A randomized pilot clinical trial of the safety of pioglitazone in treatment of patients with Alzheimer disease. Arch Neurol. 2011;68(1):45–50. doi: 10.1001/archneurol.2010.229.

Seaquist ER, Miller ME, Fonseca V, et al. Effect of thiazolidinediones and insulin on cognitive outcomes in ACCORD-MIND. J Diabetes Complications. 2013 Sep-Oct;27(5):485-91. doi: 10.1016/j.jdiacomp.2013.03.005. 

Fu H, Xie W, Curtis B, Schuster D. Identifying factors associated with hypoglycemia-related hospitalizations among elderly patients with T2DM in the US: a novel approach using influential variable analysis. Curr Med Res Opin. 2014 Sep;30(9):1787-93. doi: 10.1185/03007995.2014.922944.

Orkaby AR, Cho K, Cormack J, Gagnon DR, Driver JA. Metformin vs sulfonylurea use and risk of dementia in US veterans aged ≥65 years with diabetes. Neurology. 2017 Oct 31;89(18):1877-1885. doi: 10.1212/WNL.0000000000004586.

Abbatecola AM, Bo M, Barbagallo M, et al. Severe hypoglycemia is associated with antidiabetic oral treatment compared with insulin analogs in nursing home patients with type 2 diabetes and dementia: results from the DIMORA study. J Am Med Dir Assoc. 2015;16(4):349.e7-12. doi: 10.1016/j.jamda.2014.12.014.

Thorpe CT, Gellad WF, Good CB, et al. Tight Glycemic Control and Use of Hypoglycemic Medications in Older Veterans With Type 2 Diabetes and Comorbid Dementia. Diabetes Care. 2015;38(4):588-595. doi:10.2337/dc14-0599.

Cai XS, Tan ZG, Li JJ, et al. Glucagon-Like Peptide-1 (GLP-1) Treatment Ameliorates Cognitive Impairment by Attenuating Arc Expression in Type 2 Diabetic Rats. Med Sci Monit. 2017 Sep 8;23:4334-4342. doi:10.12659/MSM.903252.

Li Y, Duffy KB, Ottinger MA, et al. GLP-1 Receptor Stimulation Reduces Amyloid-β Peptide Accumulation and Cytotoxicity in Cellular and Animal Models of Alzheimer’s Disease. J Alzheimers Dis. 2010;19(4):1205-19. doi: 10.3233/JAD-2010-1314. 

Velmurugan K, Bouchard R, Mahaffey G, Pugazhenthi S. Neuroprotective actions of glucagon-like peptide-1 in differentiated human neuroprogenitor cells. J Neurochem. 2012 Dec;123(6):919-31. doi: 10.1111/jnc.12036. 

Hansen HH, Fabricius K, Barkholt P, et al. Long-Term Treatment with Liraglutide, a Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist, Has No Effect on β-Amyloid Plaque Load in Two Transgenic APP/PS1 Mouse Models of Alzheimer’s Disease. PLoS One. 2016 Jul 15;11(7):e0158205. doi: 10.1371/journal.pone.0158205.

Kosaraju J, Holsinger RM, Guo L, Tam KY. Linagliptin, a Dipeptidyl Peptidase-4 Inhibitor, Mitigates Cognitive Deficits and Pathology in the 3xTg-AD Mouse Model of Alzheimer's Disease. Mol Neurobiol. 2017 Oct;54(8):6074-6084. doi: 10.1007/s12035-016-0125-7.

Jain S, Sharma B. Neuroprotective effect of selective DPP-4 inhibitor in experimental vascular dementia. Physiol Behav. 2015 Dec 1;152(Pt A):182-93. doi: 10.1016/j.physbeh.2015.09.007.

Lin B, Koibuchi N, Hasegawa Y, et al. Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice. Cardiovasc Diabetol. 2014 Oct 26;13:148. doi: 10.1186/s12933-014-0148-1.

Rizvi SM, Shakil S, Biswas D, et al. Invokana (Canagliflozin) as a dual inhibitor of acetylcholinesterase and sodium glucose co-transporter 2: advancement in Alzheimer's disease- diabetes type 2 linkage via an enzoinformatics study. CNS Neurol Disord Drug Targets. 2014;13(3):447-51. PMID: 24059302.

Sa-Nguanmoo P, Tanajak P, Kerdphoo S, et al. SGLT2-inhibitor and DPP-4 inhibitor improve brain function via attenuating mitochondrial dysfunction, insulin resistance, inflammation, and apoptosis in HFD-induced obese rats. Toxicol Appl Pharmacol. 2017;333:43-50. doi: 10.1016/j.taap.2017.08.005.

Plastino M, Fava A, Pirritano D, et al. Effects of insulinic therapy on cognitive impairment in patients with Alzheimer disease and diabetes mellitus type-2. J Neurol Sci. 2010;288(1-2):112-6.  doi: 10.1016/j.jns.2009.09.022.

Beeri MS, Schmeidler J, Silverman JM, et al. Insulin in combination with other diabetes medication is associated with less Alzheimer neuropathology. Neurology. 2008;71(10):750-757. doi:10.1212/01.wnl.0000324925.95210.6d.

Craft S, Baker LD, Montine TJ, et al. Intranasal Insulin Therapy for Alzheimer Disease and Amnestic Mild Cognitive Impairment. Arch Neurol. 2012 Jan;69(1):29-38. doi: 10.1001/archneurol.2011.233. 

Akyol A, Kiylioglu N, Bolukbasi O, Guney E, Yurekli Y. Repeated hypoglycemia and cognitive decline. A case report. Neuro Endocrinol Lett. 2003;24(1-2):54-6. PMID: 12743533.

Hambling CE, Seidu SI, Davies MJ, Khunti K. Older people with Type 2 diabetes, including those with chronic kidney disease or dementia, are commonly overtreated with sulfonylurea or insulin therapies. Diabet Med. 2017;34(9):1219-1227. doi: 10.1111/dme.13380.




DOI: https://doi.org/10.22141/2224-0721.14.1.2018.127097

Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© "Publishing House "Zaslavsky", 1997-2018

 

 Яндекс.МетрикаSeo анализ сайта Рейтинг@Mail.ru